+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Guillain-Barre Syndrome Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • ID: 4987013
  • Report
  • June 2022
  • Region: Global
  • 130 Pages
  • Mordor Intelligence

FEATURED COMPANIES

  • Annexon Inc.
  • Bayer AG
  • Biotest AG
  • Cellenkos inc.
  • CSL Limited
  • Grifols S A
The Guillain-Barre syndrome market studied was anticipated to grow with a CAGR of nearly 5.2% during the forecast period, 2022-2027.

The Guillain -barre syndrome (GBS) market is significantly impacted by COVID-19. Patients with Guillain-Barre syndrome should take extra precautions to minimize the risk of getting COVID-19. Moreover, Guillain-Barre syndrome patients may not show typical symptoms such as a high temperature, and they may also experience a higher-than-normal pain threshold, which may delay the diagnosis of COVID-19. However, according to the article by European Medicine Agency published in July 2021, said that GBS will be listed as a very rare side effect of the COVID-19 Vaccine such as the Janssen COVID-19 vaccine. Such instances, are hampering the market growth.

The major factors attributing to the growth of the GBS market are the increasing geriatric population leading to the prevalence of immune disorders like multiple sclerosis, acute motor axonal neuropathy, and others. Furthermore, rise in infections due to Epstein-Barr virus, Zika virus, and others, due to the resultant higher demand for treatment. For instance, according to the study titled "Global, regional, and national burden of Guillain-Barré syndrome and its underlying causes from 1990 to 2019" published in the Journal of Neuroinflammation in November 2021, in total, 150,095 cases of GBS were reported worldwide in 2019. Between 1990 and 2019, the age-standardised prevalence of GBS per 100,000 population increased by 6.4 percent globally. In 2019, the highest and lowest age-standardised prevalence rates (per 100,000) were found in high-income Asia Pacific and East Asia, respectively.

Additionally, rise in the geriatric population anticipated the market growth over the forecast period. for instance, according to the World Health Organization 2021 updates, by 2030, 1 out of every 6 people on the planet will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of people aged 60 and above will get double to reach 2.1 billion. Between 2020 and 2050, the number of people aged 80 and above is expected to triple, reaching 426 million.

in addition, rise in new product approvals due to accelerated drug approval initiative by United States Food and Drug Administartion Approval is boosting the market growth. For instance, in September 2019, Annexon Biosciences revealed that the United States Food and Drug Administartion has granted fast track designation to ANX005, a novel treatment for Guillain-Barré syndrome.

However, higher challenges in development stage and expensive patented products and lack of awareness of disease and effective treatment in the developing economies are the major restraining factor for the market studied.

Key Market Trends


Intravenous Immunoglobulins are Expected to Hold the Large Market Share Over the Forecast Period


Intravenous immunoglobulin (IVIG) therapy is the use of a mixture of antibodies (immunoglobulins) to treat health conditions, including primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain-Barré syndrome, and certain other infections. Depending on the formulation, it can be injected into the muscle, a vein, or under the skin.

Intravenous immunoglobulins are expected to account for a large share in the market which can be attributed to the availability of a wide range of IVIG products such as Gamunex, Gammagard, and Privigen in the market and increased adoption of treatment by off-label use of intravenous immunoglobulins due to rising prevalence of multifocal motor neuropathy, dermatomyositis, polymyositis, stiff person syndrome, and relapsing-remitting multiple sclerosis.

Furthermore, according to the Foundation for Peripheral Neuropathy report published in June 2019, GBS affects about 3,000-6,000 people each year in the United States fueling the demand for the effective treatment which is expected to drive the global GBS market during the forecast period. In addition, the rise in early approvals by regulatory agencies for intravenous immunoglobulin (IVIG) products along with rising government support to increase plasma yield are likely to drive the market during the forecast period. For instance, in November 2021, study title "Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome" under the clinical trail phase by Assiut University expected to completed by Decmber 2022. such clinical studies may lead to the development of new product in future and thus expected to drive the growth of market segment.

Thus, all aforementioned factor expected to boost the segment growth over the forecast period.



North America Dominates the Market and Expected to do Same in the Forecast Period.


North America is expected to dominate the overall GBS market throughout the forecast period. The dominance is due to several factors such as the increasing geriatric population who are more prone to infections due to decreased immunity leading to high demand for effective therapy in the region. For instance, according to the report published by the Centers for Disease Control & Prevention (CDC) in December 2019, people of any age group can develop GBS, but the prevalence of GBS is at increases in people aged over 50 years which necessitates huge demand due to presence of huge geriatric population in the United States.

As aging results in the decline of the normal functioning of organ systems including the immune system, the geriatric population is highly prone to skin diseases. According to the data from World Population Prospects in September 2021, in 2020, there are an estimated 727 million persons aged 65 years or over worldwide. This number is projected to more than double by 2050. In terms of convenience, the geriatric population with skin diseases prefers to use topical steroids. All these factors together support that Guillain- Barre Syndrome market

Also, the presence of key pharmaceutical companies investing in the research activities to develop novel products and the regulatory bodies such as the United States Food and Drug Administartion which create awareness about the disease and treatment are likely to attribute to the growth of the market in the region propelling the global GBS market revenue in the forecast period.



Competitive Landscape


The global Guillain-Barre syndrome market is moderately competitive and consists of several major players. Few of the prominent players currently dominating the market are applying various strategies like acquiring the products or other companies to consolidate their market positions across the globe and while others are applying for Investigational New Drug (IND) application approvals with huge product pipelines coupled with government initiatives to increase plasma yield. Some of the companies which are currently dominating the market are Grifols S A, CSL Limited, Octapharma AG, Kedrion Biopharma Inc and Takeda Pharmaceutical Company Limited.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support


This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Annexon Inc.
  • Bayer AG
  • Biotest AG
  • Cellenkos inc.
  • CSL Limited
  • Grifols S A

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Global Prevalence of GBS and Geriatric Population
4.2.2 Rise in New Product Approvals due to Accelerated Drug Approval Initiative by USFDA
4.3 Market Restraints
4.3.1 Higher Challenges in Development Stage and Expensive Patented Products
4.3.2 Lack of Awareness of Disease and Effective Treatment in the Developing Economies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Therapeutics
5.1.1 Intravenous Immunoglobulin
5.1.2 Plasma Exchange
5.1.3 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 CSL Limited
6.1.2 Takeda Pharmaceutical Company Limited
6.1.3 Grifols S A
6.1.4 Octapharma AG
6.1.5 Bayer AG
6.1.6 Kedrion Biopharma Inc
6.1.7 China Biologic Products Holdings Inc
6.1.8 Biotest AG
6.1.9 Annexon Inc.
6.1.10 Cellenkos inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • Grifols S A
  • Octapharma AG
  • Bayer AG
  • Kedrion Biopharma Inc
  • China Biologic Products Holdings Inc
  • Biotest AG
  • Annexon Inc.
  • Cellenkos inc.
Note: Product cover images may vary from those shown

Loading
LOADING...